The report provides a detailed analysis essential for establishing a methsuximide production plant. It encompasses all critical aspects necessary for methsuximide production, including the cost of methsuximide production, methsuximide plant cost, methsuximide production costs, and the overall methsuximide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a methsuximide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Methsuximide is a succinimide-class anticonvulsant that elevates the seizure threshold by binding to T-type voltage-sensitive calcium channels. It suppresses paroxysmal spike-and-wave patterns in the brain to control absence (petit mal) seizures, characterised by brief lapses in awareness, staring spells, or automatisms. It is mainly used in cases refractory to other agents like ethosuximide. It is used for childhood and adult epilepsy patients where first-line therapies fail. It is administered orally as capsules at doses starting from 300 mg daily.
It provides prolonged efficacy through motor cortex depression and reduced neuronal excitability. It is not effective for generalised tonic-clonic or partial seizures, but plays an important role in specialised neurology for drug-resistant absence epilepsy. Its common side effects include drowsiness, dizziness, or rare hematologic problems.
The market for methsuximide is driven by the expanding epilepsy therapeutics market. The demand for succinimide-class agents in managing refractory absence (petit mal) seizures unresponsive to first-line options like ethosuximide contributes to its market demand. Its utilisation in pediatric and adult patients boosts its demand. The industrial methsuximide procurement is affected by neurology hospital formularies and epilepsy centres prioritising its adjunctive role in drug-resistant cases. The improved diagnostics, ageing populations, and trauma-related incidences further fuel its demand. Other factors like supply chains relying only on generic API manufacturers, strict stability requirements for oral capsules, along with regulatory monitoring for rare hematologic or hepatic risks impacts its sourcing strategies.
Raw Material for Methsuximide Production
According to the methsuximide production plant project report, the key raw materials used in the production of methsuximide include 2-methyl-2-phenylsuccinic anhydride, methylamine, and solvent.
Production Process of Methsuximide
The extensive methsuximide production cost report consists of the following major industrial production process:
- From 2-methyl-2-phenylsuccinic anhydride: The production process of methsuximide involves a condensation reaction. In this process, 2-methyl-2-phenylsuccinic anhydride reacts with methylamine in a suitable solvent. It promotes ring closure to the five-membered succinimide via nucleophilic attack, dehydration, and cyclisation. The reaction mixture is then refluxed, and water and excess amine are distilled off to get the crude product. The product is purified by recrystallisation from ethanol or aqueous solvents to get pure methsuximide as the final product.
Methsuximide is a succinimide anticonvulsant with the molecular formula C12H13NO2 and molecular weight of 203.24 g/mol. It appears as a white to grayish-white crystalline powder that is freely soluble in alcohol. Its structure has (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione with a pyrrolidine ring fused to phenyl and two chiral centres. It shows moderate lipophilicity with no hydrogen bond donors, two acceptors, a polar surface area of 37.4 Ų, and one rotatable bond. It has a melting point around 52.5 °C that supports its oral capsule formulation. All these physical and chemical properties makes its useful as an anticonvulsant.
